Study tests if potent weed vapes lead to overconsumption
NCT ID NCT07105449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether regular cannabis users can adjust how much they vape when using high-potency concentrates (30%, 60%, and 90% THC). Researchers will measure blood THC levels, puffing behavior, and subjective feelings of intoxication. The goal is to understand if people naturally limit their intake with stronger products, which could inform safety regulations.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cannabis (THC concentrates at 30%, 60%, and 90% potency)
- What this could lead to
- If successful, this study could provide evidence to guide regulations on high-potency cannabis products, potentially reducing public health risks like addiction and psychosis.
- What could go wrong
- This is a small, early-phase study with only 48 participants, so results may not apply to all users. It focuses on acute effects, not long-term harms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 48 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 19-55 years. * Frequency of primary exposure to cannabis 1-4 occasions per week, through any route of administration, over the past three months; participants must report experience with vaping high-potency liquid concentrates with more than 3 exposures to 90% THC and willingness to use such products in the study. * Refrain from cannabis for 48 hours and from alcohol for 12 hours before visits. * Agree not to drive a car for 24 hours after each visit. * Abstain from recreational drugs for at least 48 hours prior to each visit. * Abstain from any drugs not medically required. * Well-controlled blood pressure for participants with hypertension. Exclusion Criteria: * Pregnant/breastfeeding (women of childbearing potential must have a negative pregnancy test and report use of appropriate contraception). * Evidence of cardiac arrhythmias/failure, ischaemic heart disease. * Recent open heart/open chest surgery or cataract surgery. * Evidence from Structured Clinical Interview for DSM-5 \[SCID-5-CT\] or clinical evaluation of lifetime psychotic disorder/schizophrenia or bipolar disorder; family history of a first-degree relative with a diagnosis of psychotic disorder or schizophrenia; history of psychiatric co-morbidities in the past year (major depression, anxiety disorder or suicide attempt in past year or current suicidal ideation) and current substance use disorder/dependence. * Evidence of neurological illness (e.g., stroke, epilepsy, traumatic brain injury). * Renal or hepatic abnormalities (self-report and blood hematology/chemistry); and * Respiratory diseases, including asthma and physician-diagnosed lung disease. * Taking prescribed medications that contain either THC or cannabidiol (CBD). * Participation in another clinical or non-therapeutic study in the last three months. * Bleeding disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Ontario, M5T 1R8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Citrus compound meets cannabis: scientists study their combined effects
- Cannabis compounds tested to fight HIV brain inflammation
- Can a puff of cannabis stop a migraine? small study investigates
- THC sleep study: frequent vs. rare users under the microscope
- CBD vs THC: can cannabidiol take the edge off cannabis's psychoactive effects?
- Yale researchers scan brains to see how THC impairs memory